Navigation Links
Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
Date:3/13/2013

JUPITER, FL, March 13, 2013 The Scripps Research Institute (TSRI) and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

The new agreement extends an initial collaboration launched in 2010 between scientists on the Florida campus of TSRI and Envoy Therapeutics that led to several breakthroughs in identifying potential new compounds for neurological and psychiatric diseases. Envoy was acquired by Takeda Pharmaceuticals last November.

"We're pleased to expand our partnership with Takeda-Envoy and to push promising drug discovery efforts forward," said Scott Forrest, TSRI's vice president for business development.

"The high-throughput screening capability at Scripps Florida campus is in increasing demandboth from other research institutes and from industry."

Scripps Florida's state-of-the art high-throughput screening facility is part of its larger translational research infrastructure. The facility has expertise in transforming slow, labor-intensive biological and biochemical bench-top experiments into high-throughput screening experiments ("screens"). Fully automated robotic screening platforms then rapidly test more than 650,000 drug-like compounds for pharmacologic activity. After completion of the screens, the facility uses other cutting-edge technologies to support the development of clinically relevant compounds.

Stephen Hitchcock, senior vice president of drug discovery at Envoy said, "We originally came to Jupiter because of Scripps Florida and are thrilled that the potential of our original collaboration has been realized. Now we're moving into new therapeutic areas with different biological targets. The first step is to find small molecules that can validate those targetsand Scripps Florida is amongst the very best places to do that."

Hitchcock said that one intangible factor in the expanded research collaboration was the quality of the people at Scripps Florida. "They have been great collaborators and great friends," he said. "The interaction between our scientists and theirs was a huge factor in expanding our research."

Peter Hodder, who directs the high-throughput screening facility at Scripps Florida, has been collaborating with Hitchcock and Envoy scientists since the company's founding in 2010.

"This new effort deepens our commitment to validating novel drug discovery targets via screening-based approaches and also underlines Scripps' intrinsic worth to our partners in early-stage drug discovery research."


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
3. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
4. Scripps Research Institute scientists develop antidote for cocaine overdose
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
7. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
8. Scripps Florida scientists identify neurotranmitters that lead to forgetting
9. Plastic trash altering ocean habitats, Scripps study shows
10. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
11. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology: